<DOC>
	<DOC>NCT00402909</DOC>
	<brief_summary>This study will assess the safety and efficacy of adding nateglinide to treatment with basal insulin glargine, metformin and/or thiazolidinedione (pioglitazone or rosiglitazone), for patients with type 2 diabetes who are not achieving glycemic control with glargine, metformin and/or thiazolidinedione only.</brief_summary>
	<brief_title>Safety and Efficacy of Nateglinide in Patients With Type 2 Diabetes Already Taking Insulin Glargine, Metformin and/or Pioglitazone or Rosiglitazone</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Rosiglitazone</mesh_term>
	<mesh_term>Nateglinide</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<mesh_term>2,4-thiazolidinedione</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Male/female, age 1878 inclusive Type 2 diabetes, taking glargine, metformin and/or thiazolidinedione for 3 months prior to screening, stable doses for 2 months prior to screening HbA1c 7.08.5% inclusive Fasting plasma glucose &lt;240 mg/dL at screening Body Mass Index 2241 kg/m2 Pregnant or nursing Other investigational drugs within 30 days of screening Treatment with other antidiabetic medications other than metformin, glargine and/or thiazolidinedione History of type 1 diabetes Abnormal kidney function History of acute diabetic complications Congestive heart failure requiring treatment Myocardial infarction, coronary artery surgery, stroke within 6 months of screening Liver disease, liver enzymes more than 3 times upper limit of normal Fasting triglycerides &gt;700 mg/dL within past 12 weeks Acute infections or other conditions that may affect blood sugar or may interfere with interpretation of study data Treatment with corticosteroids Blood donation within past 12 weeks Other protocoldefined inclusion/exclusion criterial may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>78 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Type 2 diabetes,</keyword>
	<keyword>fasting glucose,</keyword>
	<keyword>postprandial glucose,</keyword>
	<keyword>blood sugar,</keyword>
	<keyword>HbA1c,</keyword>
	<keyword>insulin,</keyword>
	<keyword>glargine,</keyword>
	<keyword>metformin,</keyword>
	<keyword>thiazolidinedione</keyword>
</DOC>